恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

载药微球经动脉化疗栓塞联合阿帕替尼治疗晚期肝细胞癌的安全性和有效性-ag捕鱼平台

文字: 2019-8-29    浏览次数:390    


rationale and objective: the goal of this study was to determine the clinical efficacy and safety of drug-eluting bead (deb) transarterial chemoembolization (tace) in combination with apatinib administration in patients with advanced hepatocellular carcinoma (hcc).

目的:本研究旨在确定载药微球(deb)经动脉化疗栓塞(tace)联合阿帕替尼治疗晚期肝细胞癌(hcc)的临床疗效和安全性。

materials and methods: from december 2015 to may 2017, a total of 32 patients with advanced hcc treated with deb-tace combined with apatinib were consecutively enrolled in this study. the treatment response and laboratory outcomes were assessed at the first- and third month after deb-tace therapy. overall survival, progression-free survival, and adverse events were also analyzed and assessed.

材料和方法:自2015年12月至2017年5月,连续纳入32例晚期hcc患者,采用deb-tace (callispheres 300-500μm 载吡柔比星60-80 mg)联合阿帕替尼进行治疗。在deb-tace治疗后的第1个月和第3个月评估治疗反应和实验室结果。对总体生存、无进展生存期和不良事件亦进行分析和评估。

results: the objective response rate and disease control rate were 62.5% and 96.9% at the first month after treatment, respectively. at the third month after the first therapy, a slightly higher objective response rate (68.8%) and lower disease control rate (90.6%) were achieved. there were no differences in the levels of aspartate aminotransferase, alanine aminotransferase, serum albumin, or total bilirubin at m1 or m3 compared to m0 (all p> 0.05). the median progression-free survival was 9.5 months (95% confidence interval, 8.1-10.9 months), and the median overall survival was 22.0 months (95% confidence interval, 20.2-23.9 months). among the 32 patients, 2 had hypertension and 1 had grade 3 diarrhea; the rest of the patients had mild to moderate adverse reactions that were acceptable, and no serious adverse reactions occurred.

结果:治疗后第1个月的客观缓解率为62.5%,疾病控制率为96.9%。在第一次治疗后的第3个月,客观缓解率略微升高(68.8%),疾病控制率有所降低(90.6%)。与m0相比,m1或m3时天冬氨酸转氨酶、丙氨酸转氨酶、血清白蛋白或总胆红素水平无显著差异(均为p >0.05)。中位无进展生存期为9.5个月(95%ci,8.1-10.9个月),中位总生存为22.0个月(95%ci,20.2-23.9个月)。32例患者中有2例高血压,1例腹泻;其余患者为轻至中度不良反应,均可接受,无严重不良反应发生。

conclusion: deb-tace combined with apatinib is a safe and promising treatment approach for patients with advanced hcc.

结论:deb-tace联合阿帕替尼治疗晚期hcc是一种安全、具有前景的方法。